13F reference period
Q2 2026
Security Snapshot
Drugs Made In America Acquisition II Corp. - Ordinary Shares (DMII) Institutional Ownership
CUSIP: G2851K104
13F Institutional Holders and Ownership History from Q4 2025 to Q3 2026
Institutions Reporting
70
Shares (Excl. Options)
45.48M
Full value: 45,479,691 · shares · 30 Jun 2026Price
$10.06
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares
- Symbol
- DMII on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 45,479,691
- Total 13F value
- $457,571,530
- Portfolio coverage rank
- 0%
- Share change
- +1,551,822
- Value change
- +$15,857,769
- Number of holders
- 70
- Shares outstanding
- 65,767,971
- SEC-reported price per share
- $10.19
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- DMII - Drugs Made In America Acquisition II Corp. - Ordinary Shares is tracked under CUSIP G2851K104.
- 70 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 68 to 70 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$438.12M
Full value: $438,116,987 · USD · 31 Mar 2026.$457.57M
Full value: $457,571,530 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 70 institutions filings for Q2 2026.
Security key
G2851K104
13F reference period
Q2 2026
13F holders
70
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
DMII full holder history
Drugs Made In America Acquisition II Corp. SEC filings
Drugs Made In America Acquisition II Corp. company facts
Drugs Made In America Acquisition II Corp. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G2851K104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
DMII
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Drugs Made In America Acquisition II LLC | 10% | 6,708,333 | Drugs Made In America Acquisition II LLC | 01 Oct 2025 |
As of 30 Jun 2026,
70
institutional investors reported holding
shares of
Drugs Made In America Acquisition II Corp. - Ordinary Shares (DMII).
This represents
69%
of the company’s total
outstanding shares.
45.48M
Full value: 45,479,691 · shares · 30 Jun 202665.77M
Full value: 65,767,971 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
54%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Karpus Management, Inc. | 4.2% | 2,787,998 | +7.3% | 0.81% | $28,047,260 |
| MMCAP International Inc. SPC | 4.1% | 2,700,000 | 0% | 2.3% | $27,162,000 |
| Magnetar Financial LLC | 4.1% | 2,700,000 | 0% | 0.25% | $27,162,000 |
| GLAZER CAPITAL, LLC | 3.6% | 2,343,278 | -0.28% | 0.58% | $23,573,000 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 3.4% | 2,241,215 | +896% | 0.77% | $22,569,035 |
| MILLENNIUM MANAGEMENT LLC | 3% | 1,993,558 | +0.87% | 0.01% | $20,055,193 |
| Hudson Bay Capital Management LP | 3% | 1,969,030 | 0% | 0.09% | $19,808,442 |
| WOLVERINE ASSET MANAGEMENT LLC | 2.8% | 1,855,222 | +3.3% | 0.24% | $18,663,533 |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 2.3% | 1,500,000 | 0% | 0.21% | $15,090,000 |
| Polar Asset Management Partners Inc. | 2.3% | 1,500,000 | 0% | 0.28% | $15,090,000 |
| D. E. Shaw & Co., Inc. | 2.2% | 1,475,000 | +6.1% | 0.01% | $14,838,500 |
| AQR Arbitrage LLC | 1.7% | 1,131,266 | +1.7% | 0.16% | $11,380,536 |
| Crossingbridge Advisors, LLC | 1.7% | 1,100,000 | +214% | 2% | $11,066,000 |
| ARISTEIA CAPITAL, L.L.C. | 1.7% | 1,100,000 | 0% | 0.17% | $11,066,000 |
| First Trust Capital Management L.P. | 1.6% | 1,067,798 | 0% | 0.63% | $10,742,048 |
| OMERS ADMINISTRATION Corp | 1.5% | 1,000,000 | 0% | 0.06% | $10,060,000 |
| Davidson Kempner Capital Management LP | 1.5% | 1,000,000 | 0% | 0.16% | $10,060,000 |
| PICTON MAHONEY ASSET MANAGEMENT | 1.4% | 888,000 | +1.5% | 0.08% | $8,933,283 |
| TWO SIGMA INVESTMENTS, LP | 1.3% | 886,544 | 0% | 0.01% | $8,918,633 |
| Mercuria Capital Strategies, LLC | 1.1% | 750,000 | 0% | 4.6% | $7,545,000 |
| Ghisallo Capital Management LLC | 1.1% | 750,000 | 0% | 0.15% | $7,545,000 |
| Context Capital Management, LLC | 1.1% | 750,000 | 0% | 0.15% | $7,545,000 |
| MOORE CAPITAL MANAGEMENT, LP | 1.1% | 750,000 | 0% | 0.17% | $7,545,000 |
| Westchester Capital Management, LLC | 0.95% | 621,797 | +24% | 0.31% | $6,255,278 |
| Radcliffe Capital Management, L.P. | 0.88% | 575,721 | 0% | 0.44% | $5,791,753 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Headline period
Q2 2026
Rows shown
1-4 of 4